Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg: Pooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies

By Göretzlehner Gunther  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 269-277

Adis International

Access to resources Recommend Favorite

Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®): A 13-Cycle, Observational Study in Routine Clinical Practice

By Pushparajah Daphnee S.  

Clinical Drug Investigation, Vol. 31, Iss. 2, 2011-02 ,pp. : 121-134

Adis International

Access to resources Recommend Favorite

Six-Month Evaluation of the Benefits of the Low-Dose Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg in Young Women: Results of the Prospective, Observational, Non-Interventional, Multicentre TeeNIS Study

By Anthuber Sabine  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 211-220

Adis International

Access to resources Recommend Favorite

Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/ Ethinylestradiol 0.03mg (Belara): Results of a Post-Marketing Surveillance Study

By Schramm G.   Steffens D.  

Clinical Drug Investigation, Vol. 22, Iss. 4, 2002-01 ,pp. : 221-231

Adis International

Access to resources Recommend Favorite

Ethinylestradiol/Chlormadinone Acetate

By Curran M.P.   Wagstaff A.J.  

Drugs, Vol. 64, Iss. 7, 2004-01 ,pp. : 751-760

Adis International

Access to resources Recommend Favorite